Mesoblast Limited (ASX:MSB): Ryoncil Revenue, Cash Spending and Clinical Programs

Aditi Sarkar

22 October 2026 04:20 PM AEDT

Mesoblast Limited (ASX:MSB): Ryoncil Revenue, Cash Spending and Clinical Programs

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Mesoblast (ASX:MSB) reported quarterly Ryoncil net revenue of US$28 million, up 44% year on year.
Net operating cash spending fell to US$2.3 million from US$14.9 million in the comparable period.
Cash stood at US$99 million at 30 September 2026, the company reported.
The company is progressing programs in chronic low back pain and other inflammatory conditions.

Mesoblast Limited (ASX:MSB) develops allogeneic, or donor-derived, cellular medicines for severe inflammatory conditions, with commercial activity centred on its Ryoncil therapy in the United States. Its October 2026 quarterly update reported higher Ryoncil revenue and reduced net operating cash spending. At the time of writing on 22 October 2026, Mesoblast (ASX:MSB) was quoted at AUD 1.86, with a daily change of 0.00%. The trading figure does not establish a connection with any specific company announcement.

Company Business

The company develops treatments using its mesenchymal lineage cell technology platforms. Ryoncil (remestemcel-L-rknd) is approved in the United States for steroid-refractory acute graft-versus-host disease in paediatric patients aged two months and older. This condition can arise following stem-cell transplantation and is treated in specialist care settings. Mesoblast (ASX:MSB) is also investigating other indications for remestemcel-L and its separate rexlemestrocel-L platform.

Its clinical programs cover inflammatory conditions and chronic low back pain, while the company has disclosed collaborations in Japan, Europe and China. Mesoblast manufactures cryopreserved cell-based products intended for distribution to healthcare providers. Manufacturing capacity, quality testing and distribution arrangements are important operational considerations because cellular products must satisfy regulatory standards before clinical or commercial use.

Recent Development

In mid-October 2026, Mesoblast (ASX:MSB) reported preliminary results for the fiscal quarter ended 30 September. Ryoncil net revenue reached US$28 million, compared with US$19 million in the corresponding prior-year quarter. Management said September recorded the highest number of new patient starts during the quarter and referred to seasonal treatment scheduling in July and August.

The company identified 54 onboarded treatment sites in its October announcement. Earlier, in September 2026, it reported US Food and Drug Administration approval of a new potency assay for commercial Ryoncil. Regulatory acceptance of testing methods matters for the release and consistency of manufactured cell therapy batches, although it does not itself establish outcomes for separate investigational programs.

During August 2026, Mesoblast also reported progress in its pivotal Phase 3 trial involving chronic low back pain. The program uses rexlemestrocel-L and remains distinct from the approved paediatric Ryoncil indication. Clinical trial milestones and commercial treatment-site activity therefore represent different categories of evidence when evaluating the company’s disclosed operations.

Financial Performance and Sector Context

Mesoblast (ASX:MSB) recorded an 85% reduction in net operating cash spending for the September 2026 quarter, to US$2.3 million from US$14.9 million in the comparable period. The company reported a cash balance of US$99 million at 30 September 2026. These figures describe quarterly cash use and available liquidity; they should not be treated as measures of net profit or audited full-year earnings.

The October announcement stated that the quarterly results were preliminary management estimates, subject to normal closing and audit procedures. Ryoncil is sold into a specialised US treatment market, where patient eligibility, physician decisions, reimbursement arrangements and site onboarding can influence sales timing. This combination means quarterly revenue and patient starts may vary without necessarily implying a corresponding change in the longer-term clinical program.

The business also faces the sector-wide cost of clinical development and regulated manufacturing. Mesoblast (ASX:MSB) must allocate resources between expanding commercial product supply, conducting trials and pursuing additional regulatory submissions. Cash balances can change with expenditure, receipts and financing arrangements, so subsequent reporting periods will be important for establishing whether reduced operating cash spending persists.

Risks to Consider

Commercial concentration in Ryoncil exposes Mesoblast to uptake, reimbursement and treatment-site utilisation risks. For investigational therapies, trial outcomes may not support registration or wider clinical use. Regulatory reviews can require additional evidence, while production scale-up depends on manufacturing consistency and quality controls. The company’s disclosed cash position is material, but future development and commercial expenditure remains a financing consideration.

What to Watch Next

Further updates from Mesoblast (ASX:MSB) may clarify Ryoncil patient starts, quarterly revenue and the number of active treatment sites. Its next cash-flow report can show whether lower operating cash spending continued beyond September. Investors may also monitor progress in the chronic low back pain Phase 3 program, additional regulatory steps and any changes to clinical-development priorities.

Key Insights

Mesoblast entered its FY27 reporting cycle with US$28 million of quarterly Ryoncil revenue, lower net operating cash spending and US$99 million of reported cash at the end of September. The business combines a marketed US paediatric cell therapy with investigational indications. Subsequent disclosures will help distinguish ongoing commercial trends from clinical milestones and will provide further evidence about spending and liquidity.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.